Hence, our findings support that palbociclib selectively suppresses GBM with wild-type PTEN, providing preclinical evidence and a proof-of-concept that CDK4/6 inhibitors are promising drugs for GBM treatment. This evidence concerns the gene CDK4 and glioblastoma.